Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
83 hedge funds and large institutions have $247M invested in Generation Bio in 2023 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 27 increasing their positions, 29 reducing their positions, and 23 closing their positions.
962% more call options, than puts
Call options by funds: $138K | Put options by funds: $13K
11% more capital invested
Capital invested by funds: $223M → $247M (+$24M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 9.62% → 9.62% (-0%)
7% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 29
13% less funds holding
Funds holding: 95 → 83 (-12)
52% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$9.46M |
| 2 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$2.01M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.85M |
| 4 |
ACM
Atika Capital Management
New York
|
+$1.72M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$538K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.91M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.56M |
| 3 |
BlackRock
New York
|
-$1.27M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$1.23M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$952K |
GBIO Hedge Fund Activity: Q1 2023 in Review
83 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q1 2023, worth a combined $247M — up 11% from $223M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of GBIO and 11 opened new positions — a net loss of 12 holders — while 29 trimmed existing stakes and 27 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $9.46M. The largest seller was Farallon Capital Management, exiting entirely with an estimated $4.91M sold.
- 83 institutional investors held Generation Bio (GBIO) as of Q1 2023, down from 95 in Q4 2022.
- Funds reported $247M of Generation Bio stock for Q1 2023, up 11% quarter-over-quarter.
- 11 funds opened new Generation Bio positions in Q1 2023 and 23 closed out, a net change of -12 holders.
- The largest Generation Bio buyer in Q1 2023 was EcoR1 Capital, an estimated $9.46M added.
- The largest Generation Bio seller in Q1 2023 was Farallon Capital Management, an estimated $4.91M sold.
Based on aggregated 13F filings for Q1 2023.